Drugs / Cobolimab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04446351 | Jun 2020 → Dec 2026 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03307785 | Oct 2017 → Feb 2020 | metastatic malignant neoplasm, non-small cell lung carcinoma | Tesaro, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02817633 | Jul 2016 → Mar 2027 expected | neoplasm | Tesaro, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02723955 | Jun 2016 → Jul 2023 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06521567 | Mar 2025 → Oct 2026 expected | Hodgkins lymphoma, diffuse intrinsic pontine glioma, ependymoma, fibrolamellar hepatocellular carcinoma +5 | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06238635 | Mar 2024 → Dec 2026 expected | cervical carcinoma | Meghan Shea | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04139902 | Jun 2020 → Sep 2025 overdue | melanoma | Diwakar Davar | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03680508 | Dec 2019 → Mar 2026 overdue | adult hepatocellular carcinoma | University of Hawaii | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04655976 | Dec 2020 → Jun 2025 overdue | non-small cell lung carcinoma | GlaxoSmithKline | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-05 | AnaptysBio, Inc. | Results AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials anaptysbio.com ↗
COSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO , Inc. (GSK) as part of the same collaboration agreement as JEMPERLI, achieved pre-specified efficacy and safety criteria |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-05 | AnaptysBio, Inc. | AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials anaptysbio.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cobolimab | “Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042)” NCT04139902 ↗6“TSR-022 (cobolimab, TIM-3 binding antibody)” NCT03680508 ↗ |
| Known as | TSR-022 | “Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042)” NCT04139902 ↗ |
| Known as | WBP-296A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298123 ↗ |
| Action | Inhibit | “Tim-3 Inhibitor Cobolimab (TSR-022)” NCT04139902 ↗ |
| Modality | Monoclonal antibody | “TSR-022, an Anti-TIM-3 Monoclonal Antibody” NCT02817633 ↗ |
| Route | Intravenous | “TSR-022 900 mg, IV infusion on Day 1 Q3W” NCT03307785 ↗ |
| Target | HAVCR2 | “TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor.” NCT03307785 ↗ |